16,533 results match your criteria Hepatic Carcinoma Primary


Electrochemotherapy of cholangiocellular carcinoma at hepatic hilum: a case report.

Eur Rev Med Pharmacol Sci 2020 Jun;24(12):7051-7057

Division of Radiology, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Naples, Italy.

Objective: Cholangiocarcinoma (CCA) is the second most common primary hepatic malignancy after hepatocellular carcinoma. The current standard palliative treatment, chemotherapy regimen with gemcitabine and cisplatin, prolongs overall survival only of a few months. Established locoregional therapies are not a curative option or an alternative to surgery in the treatment of CCA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26355/eurrev_202006_21698DOI Listing

Carcinoma of unknown primary with hepatic metastases: a need of judicious and contemplative diagnostic algorithm.

Abdom Radiol (NY) 2020 Jul 6. Epub 2020 Jul 6.

Wake Forest University and Baptist Health, Medical Center Boulevard, Winston-Salem, NC, 27157, USA.

Carcinoma of Unknown Primary presenting primarily as hepatic metastases encompasses a dismal subgroup of tumors with a median survival of 5.9 months. Adenocarcinoma is the most common histological subtype identified upon biopsy and the primary tumor remains undetectable in the majority of cases despite extensive workup. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00261-020-02630-3DOI Listing

Dexmedetomidine promotes the progression of hepatocellular carcinoma through hepatic stellate cell activation.

Exp Mol Med 2020 Jul 6. Epub 2020 Jul 6.

Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, 510315, Guangzhou, China.

Dexmedetomidine (DEX) is an anesthetic that is widely used in the clinic, and it has been reported to exhibit paradoxical effects in the progression of multiple solid tumors. In this study, we sought to explore the mechanism by which DEX regulates hepatocellular carcinoma (HCC) progression underlying liver fibrosis. We determined the effects of DEX on tumor progression in an orthotopic HCC mouse model of fibrotic liver. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s12276-020-0461-6DOI Listing

Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma.

J Exp Clin Cancer Res 2020 Jul 6;39(1):126. Epub 2020 Jul 6.

Department of Gastroenterology, Putuo People's Hospital, Tongji University School of Medicine, number 1291, Jiangning road, Putuo, Shanghai, 200060, China.

Liver cancer has become the sixth most diagnosed cancer and the fourth leading cause of cancer death worldwide. Hepatocellular carcinoma (HCC) is responsible for up to 75-85% of primary liver cancers, and sorafenib is the first targeted drug for advanced HCC treatment. However, sorafenib resistance is common because of the resultant enhancement of aerobic glycolysis and other molecular mechanisms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13046-020-01629-4DOI Listing

A case report of a patient with bulky uterine cervical neoplasm who achieved complete response with "intentional internal high-dose policy" high-dose-rate interstitial brachytherapy.

Medicine (Baltimore) 2020 Jul;99(27):e20860

Department of Radiation Therapy, National Cancer Center Hospital, Tokyo.

Rationale: Gynecological high-dose-rate (HDR) brachytherapy has progressed for years, but it remains difficult for bulky tumors to be controlled locally. Dose limitations to organs at risk (OARs) are invariably obstacles in increasing the prescription dose. Additionally, it is controversial that the excessive hyperdose sleeve, the volume receiving a dose equal to or greater than twice the reference dose, should be eliminated in gynecological HDR brachytherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000020860DOI Listing

Does intermittent Pringle maneuver loss its clinical value in reducing bleeding during hepatectomy? A systematic review and meta-analysis.

Int J Surg 2020 Jul 3. Epub 2020 Jul 3.

Department of Hepatopancreatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University; Department of Laboratory, Fujia Medical University Union Hospital. Electronic address:

Background: The intermittent Pringle's maneuver (IPM) is conducted mainly during the procedure of hepatectomy to control intraoperative blood loss (IBL), but it has been questioned since improvement of surgical technology and intraoperative management. Hence, we conducted a systematic review and meta-analysis to validate the clinical value of IPM.

Materials And Methods: Eligible studies that were designed to evaluate the IPM in the procedure of hepatectomy were searched for on PubMed, Medline, and other databases from establishment of the database to October 2019. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijsu.2020.06.034DOI Listing

Identification of prognostic and metastasis-related alternative splicing signatures in hepatocellular carcinoma.

Biosci Rep 2020 Jul 6. Epub 2020 Jul 6.

Department of Orthopaedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

As the most common neoplasm in digestive system, hepatocellular carcinoma (HCC) is one of the most important leading cause of cancer death worldwide. Its high-frequency metastasis and relapse rate lead to the poor survival of HCC patients. However, the mechanism of HCC metastasis is still unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1042/BSR20201001DOI Listing

Long non‑coding RNA FLVCR1‑AS1 promotes glioma cell proliferation and invasion by negatively regulating miR‑30b‑3p.

Mol Med Rep 2020 May 15. Epub 2020 May 15.

Department of Blood Transfusion, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China.

Glioblastoma (GBM) is the most common and malignant primary brain tumor in adults that originates from glial cells. The prognosis of patients with high‑grade glioma is poor. It is therefore crucial to develop effective therapeutic strategies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/mmr.2020.11149DOI Listing

Breath Metabolomics Provides an Accurate and Noninvasive Approach for Screening Cirrhosis, Primary, and Secondary Liver Tumors.

Hepatol Commun 2020 Jul 26;4(7):1041-1055. Epub 2020 Apr 26.

Department of Quantitative Health Sciences Lerner Research Institute Cleveland Clinic Cleveland OH.

Hepatocellular carcinoma (HCC) and secondary liver tumors, such as colorectal cancer liver metastases are significant contributors to the overall burden of cancer-related morality. Current biomarkers, such as alpha-fetoprotein (AFP) for HCC, result in too many false negatives, necessitating noninvasive approaches with improved sensitivity. Volatile organic compounds (VOCs) detected in the breath of patients can provide valuable insight into disease processes and can differentiate patients by disease status. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep4.1499DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327218PMC

Clinical Significance of Trk Receptor Expression as a New Therapeutic Target in Hepatocellular Carcinoma.

Pathol Oncol Res 2020 Jul 4. Epub 2020 Jul 4.

Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, South Korea.

Oncogenic fusion of the tropomyosin receptor kinase (Trk) receptor family encoded by the NTRK gene has been found in several carcinomas. About ten targeted therapies have been developed and clinical trials are in progress. However, the results of studies on expression of the Trk receptor in HCC have not yet been published. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12253-020-00871-7DOI Listing

Role of selected criteria and preventive chemotherapy in tumor recurrence after liver transplantation.

Hepatobiliary Pancreat Dis Int 2020 Jun 21. Epub 2020 Jun 21.

Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Key Laboratory of Organ Transplantation, Ministry of Education, Wuhan 430030, China; NHC Key Laboratory of Organ Transplantation, Wuhan 430030, China; Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan 430030, China.

Background: Long-term survival after liver transplantation (LT) for hepatocellular carcinoma (HCC) patients remains poor because of tumor recurrence. To improve the prognosis of HCC patients after LT, we aimed to identify different transplantation criteria and risk factors related to tumor recurrence and evaluate the effect of preventive chemotherapy in a single center.

Methods: In total, data on 20 variables and the survival of 199 patients with primary HCC who underwent LT between 2005 and 2015 were included for analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hbpd.2020.06.008DOI Listing

Oligometastatic adrenocortical carcinoma: the role of image-guided thermal ablation.

Eur Radiol 2020 Jul 3. Epub 2020 Jul 3.

Internal Medicine Unit, Clinical and Biological Sciences Department, University of Turin, San Luigi Gonzaga University Hospital, Regione Gonzole 10, 10043 Orbassano, Turin, Italy.

Objectives: To evaluate the impact of image-guided ablation of liver and lung metastases from adrenocortical carcinoma (ACC).

Methods: Patients with oligometastatic ACC (liver and lung metastases) who underwent image-guided ablation were retrospectively included in the study. Complete ablation (CA) at the first contrast-enhanced CT control, local tumor progression (LTP), local tumor progression-free survival (LTPFS), liver disease-free survival (LDFS), and overall survival (OS) were evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00330-020-07019-wDOI Listing

Radioembolization-induced Tumor Calcifications as a Surrogate Marker of Tumor Response in Patients With Hepatocellular Carcinoma.

Anticancer Res 2020 Jul;40(7):4191-4198

Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.

Background/aim: Tumoral calcification after chemotherapy or radiation therapy has been reported in various cancer patients, but not after radioembolization. The purpose of this study was to evaluate the prognostic value of radioembolization-induced tumor calcification of hepatocellular carcinoma (HCC) treated by radioembolization.

Patients And Methods: This retrospective study comprised patients with single nodular HCC who underwent yttrium-90 radioembolization between November 2015 and April 2019. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14419DOI Listing

Budd-Chiari Syndrome: An Uncommon Cause of Chronic Liver Disease that Cannot Be Missed.

Clin Liver Dis 2020 Aug 2;24(3):453-481. Epub 2020 Jun 2.

Section of Digestive Diseases, Yale Liver Center, Yale University School of Medicine, 333 Cedar Street, LMP 1080, New Haven, CT 06520, USA. Electronic address:

Budd-Chiari syndrome (BCS), or hepatic venous outflow obstruction, is a rare cause of liver disease that should not be missed. Variable clinical presentation among patients with BCS necessitates a high index of suspicion to avoid missing this life-threatening diagnosis. BCS is characterized as primary or secondary, depending on etiology of venous obstruction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cld.2020.04.012DOI Listing

Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial.

Lancet Oncol 2020 Jul;21(7):947-956

Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.

Background: Indications for liver transplantation for hepatocellular carcinoma are evolving and so-called expanded criteria remain debated. Locoregional therapies are able to downstage hepatocellular carcinoma from beyond to within the Milan criteria. We aimed to investigate the efficacy of liver transplantation after successful hepatocellular carcinoma downstaging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(20)30224-2DOI Listing

Synchronous tumours detected during cancer patient staging: prevalence and patterns of occurrence in multidetector computed tomography.

Pol J Radiol 2020 26;85:e261-e270. Epub 2020 May 26.

Radiology Department, National Cancer Institute Pascale Foundation, Naples, Italy.

Purpose: The incidental detection of one or more additional primary tumours during computed tomography (CT) staging of a patient with known malignancy is rare but possible. This occurrence should be considered by the radiologist when a new lesion is detected, especially if the lesion location is atypical for metastases. The purpose of this report was to document the usefulness of total body CT scan to detect synchronous primary malignancies in cancer patients undergoing a staging workup. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5114/pjr.2020.95781DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315052PMC

Follow-up schedule for initial recurrent hepatocellular carcinoma after ablation based on risk classification.

Cancer Imaging 2020 Jul 1;20(1):42. Epub 2020 Jul 1.

Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China.

Background: To date, no standard follow-up guidelines exist regarding patients receiving ablation for initial recurrent hepatocellular carcinoma (HCC). We aimed to explore whether intensive follow-up could benefit these patients.

Methods: We reviewed the clinical data of patients who received complete ablation for initial HCC recurrence after curative treatments in our institution from January 2005 to June 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40644-020-00319-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7329485PMC

Postoperative adjuvant treatment strategy for hepatocellular carcinoma with microvascular invasion: a non-randomized interventional clinical study.

BMC Cancer 2020 Jul 1;20(1):614. Epub 2020 Jul 1.

Department of Hepatobiliary Surgery, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Panjiayuan Nanli Area, Chaoyang District, Beijing, 100021, China.

Background: Microvascular invasion (MVI) is considered to be one of the important prognostic factors that affect postoperative recurrence in patients with hepatocellular carcinoma (HCC) with variable results across their treatment options. This study was carried out to investigate efficacy of postoperative adjuvant RT in HCC patients with MVI.

Methods: This was single center, prospective study carried out in HCC patients with MVI, aged 35-72 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-020-07087-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7329435PMC

One-step diagnosis. A key tool for the elimination of hepatitis C.

Rev Esp Enferm Dig 2020 Jul 2;112:513-514. Epub 2020 Jul 2.

Aparato Digestivo, Hospital Universitario Fundación Alcorcón, España.

Hepatitis C is a major cause of liver cirrhosis and hepatocellular carcinoma, as well as the primary indication for liver transplant in Europe. The highly effective direct-acting antivirals currently available make it possible to achieve the hepatitis C elimination targets set by the World Health Organization. For this, population screening and one-step diagnosis are fundamental strategies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.17235/reed.2020.7201/2020DOI Listing

The Significance of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma: Real-Time Monitoring and Moving Targets for Cancer Therapy.

Cancers (Basel) 2020 Jun 29;12(7). Epub 2020 Jun 29.

School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.

Hepatocellular carcinoma (HCC) is ranked as the sixth most common cancer around the world. With the emergence of the state-of-the-art modalities lately, such as liver transplantation, image-guided ablation, and chemoembolization, the death rate is still high due to high metastasis rate after therapy. Observation by biannual ultrasonography allows effective diagnosis at an early stage for candidates with no extrahepatic metastasis, but its effectiveness still remains unsatisfactory. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12071734DOI Listing

[Metastatic gastrointestinal hepatoid adenocarcinoma of the liver: a high-grade carcinoma that is easily confused with primary hepatocellular carcinoma].

Zhonghua Bing Li Xue Za Zhi 2020 Jul;49(7):710-714

Department of Pathology, the Affiliated Drum Tower Hospital, Nanjing University Medical School, Nanjing 210008, China; Department of Pathology, Drum Tower School of Clinical Medicine, Nanjing Medical University, Nanjing 210008, China.

To investigate the clinicopathologic and immunophenotypic features of metastatic gastrointestinal hepatoid adenocarcinomas in the liver. Eight cases of hepatic metastatic gastrointestinal hepatoid adenocarcinoma diagnosed at the Affiliated Drum Tower Hospital, Nanjing University Medical School from January 2009 to January 2019 were retrospectively analyzed. The clinical data, histopathologic features and immunohistochemical (IHC) characteristics performed by EnVision method were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.cn112151-20191123-00753DOI Listing

Tescalcin is an unfavorable prognosis factor that regulats cell proliferation and survival in hepatocellular carcinoma patients.

Cancer Commun (Lond) 2020 Jul 1. Epub 2020 Jul 1.

State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, P. R. China.

Background: Hepatocellular carcinoma (HCC) is a major health problem and a primary cause of cancer-related death worldwide. Although great advances have achieved recently by large-scale high-throughput analysis, the precise molecular mechanism underlying HCC progression remains to be clearly elucidated. We investigated the relationship between Tescalcin (TESC), a candidate oncogene, and clinicopathological features of HCC patients and explored the role of TECS in HCC development. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cac2.12069DOI Listing

Hepatocellular Expression of SIRT1 and Its Effect on Hepatocellular Carcinoma Progression: A Future Therapeutic Perspective.

Int J Hepatol 2020 13;2020:2374615. Epub 2020 Jun 13.

Department of Immunology and Molecular Biology, School of Biomedical and Laboratory Science, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.

Hepatocellular carcinoma (HCC) is an aggressive primary hepatic malignancy with a significant morbidity and mortality rate. Although chemotherapy along with surgical incision is believed to be an effective therapeutic approach, to date recurrence is being lifted a major concern. Thus, identifying another best therapeutic approach is becoming the main aim of physicians and scholars. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2020/2374615DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315277PMC

Proton versus photon radiotherapy for primary hepatocellular carcinoma: a propensity-matched analysis.

Radiat Oncol 2020 Jun 30;15(1):159. Epub 2020 Jun 30.

Department of Radiation Oncology, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan.

Background: Proton radiotherapy has a dosimetric advantage over photon radiotherapy. Many retrospective studies have shown promising results with proton radiotherapy in treating hepatocellular carcinoma (HCC). However, clinical evidence demonstrating the benefit of protons over photons is still limited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13014-020-01605-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325065PMC

Successful use of transarterial radioembolization with yttrium-90 (TARE-Y90) in two children with hepatoblastoma.

Pediatr Blood Cancer 2020 Jun 30:e28421. Epub 2020 Jun 30.

Division of Hematology/Oncology and Bone Marrow Transplantation, Nemours Children's, Specialty Care and Wolfson Children's Hospital, Jacksonville, Florida.

Primary malignant liver tumors are rare but all require surgical resection as part of therapy with curative intent. A minority of patients have resectable tumors at diagnosis. Chemotherapy has a therapeutic role in hepatoblastoma but only one-third of patients have resectable disease at diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.28421DOI Listing

Pediatric Hepatoblastoma, Hepatocellular Carcinoma, and Other Hepatic Neoplasms: Consensus Imaging Recommendations from American College of Radiology Pediatric Liver Reporting and Data System (LI-RADS) Working Group.

Radiology 2020 Jun 30:200751. Epub 2020 Jun 30.

From the Department of Radiology, University of Texas Southwestern Medical Center, Dallas, Tex (G.R.S.); Department of Radiology, University of Pittsburgh Medical Center Children's Hospital of Pittsburgh, Pittsburgh, Pa (J.H.S.); Department of Radiology, Emory University and Children's Healthcare of Atlanta, Atlanta, Ga (A.A.); Department of Diagnostic Imaging, The Hospital for Sick Children and Department of Medical Imaging, University of Toronto, Toronto, Canada (G.B.C.); Department of Radiology, Montefiore Medical Center, Bronx, NY (V.C.); Department of Radiology, Duke University Medical Center, Durham, NC (J.T.D.); Department of Radiology, Mallinckrodt Institute of Radiology, St. Louis Children's Hospital, Washington University School of Medicine, St Louis, Mo (G.K.); Department of Radiology, Nationwide Children's Hospital, Columbus, Ohio (R.K.); Stanford University School of Medicine, Lucile Packard Children's Hospital, Stanford, Calif (M.P.L.); Department of Radiology, Texas Children's Hospital, Houston, Tex (P.M.M.); Nemours Children's Hospital, Nemours Children's Health System, University of Central Florida College of Medicine, Orlando, Fla (D.J.P.); Liver Imaging Group, Department of Radiology, University of California San Diego, San Diego, Calif (C.B.S.); Department of Radiology, Cincinnati Children's Hospital, Cincinnati, Ohio (A.J.T.); and Department of Radiology, University of Cincinnati College of Medicine, 3333 Burnet Ave, MLC 5031, Cincinnati, OH 45229 (A.J.T.).

Appropriate imaging is imperative in evaluating children with a primary hepatic malignancy such as hepatoblastoma or hepatocellular carcinoma. For use in the adult patient population, the American College of Radiology created the Liver Imaging Reporting and Data System (LI-RADS) to provide consistent terminology and to improve imaging interpretation. At present, no similar consensus exists to guide imaging and interpretation of pediatric patients at risk for developing a liver neoplasm or how best to evaluate a pediatric patient with a known liver neoplasm. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.2020200751DOI Listing

Doublecortin-like kinase 1 promotes hepatocyte clonogenicity and oncogenic programming via non-canonical β-catenin-dependent mechanism.

Sci Rep 2020 Jun 29;10(1):10578. Epub 2020 Jun 29.

Department of Medicine, Section of Digestive Diseases and Nutrition, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.

Chronic liver injury is a risk factor for cirrhosis and hepatocellular carcinoma (HCC). The molecular mechanisms that regulate the decision between normal injury repair and neoplastic initiation are unclear. Doublecortin-like kinase 1 (DCLK1), a tumor stem cell marker, is induced during cirrhosis and HCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-67401-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324569PMC

Tumor necrosis as a poor prognostic predictor on postoperative survival of patients with solitary small hepatocellular carcinoma.

BMC Cancer 2020 Jun 29;20(1):607. Epub 2020 Jun 29.

State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.

Background: Small hepatocellular carcinoma (sHCC) is a special subtype of HCC with the maximum tumor diameter ≤ 3 cm and excellent long-term outcomes. Surgical resection or radiofrequency ablation provides the greatest chance for cure; however, many patients still undergo tumor recurrence after primary treatment. To date, there is no clinical applicable method to assess biological aggressiveness in solitary sHCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-020-07097-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325084PMC

Identification of Key Biological Processes, Pathways, Networks, and Genes with Potential Prognostic Values in Hepatocellular Carcinoma Using a Bioinformatics Approach.

Cancer Biother Radiopharm 2020 Jun 26. Epub 2020 Jun 26.

Department of Anesthesiology, Ruijin Hospital Affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Hepatocellular carcinoma (HCC), as one primary liver cancer type, accounts for 75%-85% of liver cancer cases. HCC is the second leading cause of cancer death in East Asia and sub-Saharan Africa and the sixth most common in western countries. Identification of key genes would facilitate the development of therapies and improve the prognosis outcomes of HCC patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/cbr.2019.3327DOI Listing

Hypoxia-induced miR-3677-3p promotes the proliferation, migration and invasion of hepatocellular carcinoma cells by suppressing SIRT5.

J Cell Mol Med 2020 Jun 28. Epub 2020 Jun 28.

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Hepatocellular carcinoma (HCC), with life-threatening malignant behaviours, often develops distant metastases and is the fourth most common primary cancer in the world, having taken millions of lives in Asian countries such as China. The novel miR-3677-3p is involved in a high-expression-related poor prognosis in HCC tissues and cell lines, indicating oncogenesis functions in vitro and in vivo. Initially, we confirmed the inhibition of proliferation, migration and invasion in miR-3677-3p knock-down MHCC-97H and SMMC-7721 cell lines, which are well known for their high degree of invasiveness. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jcmm.15503DOI Listing

Emerging Opportunities for Combining Locoregional Therapy with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.

Curr Oncol Rep 2020 Jun 29;22(8):76. Epub 2020 Jun 29.

Department of Radiology, Zhongda Hospital, Center of Interventional Radiology and Vascular Surgery, Medical School, Southeast University, 87 Dingjiaqiao Rd., Nanjing, 210009, China.

Purpose Of Review: Immunotherapy shows great promises in solid tumors. Locoregional therapy can promote systemic immune response in hepatocellular carcinoma (HCC). The combination of locoregional therapy and immune checkpoint inhibitors (ICIs) activates a synergistic effect that can enhance the potency of anti-tumor immunity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-020-00943-6DOI Listing

Hepatocellular carcinoma: recent advances and emerging medical therapies.

F1000Res 2020 17;9. Epub 2020 Jun 17.

Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong.

Hepatocellular carcinoma remains a deadly disease with poor prognosis in patients with unresectable cancer. Trans-arterial chemoembolization is the primary locoregional therapy for intermediate-stage hepatocellular carcinoma, with an estimated median overall survival of less than two years. For almost a decade, sorafenib has been the only standard systemic treatment for metastatic disease or tumors which progress or are considered unsuitable for locoregional therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12688/f1000research.24543.1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308880PMC

Synchronous Hepatocellular Carcinoma in a Patient with Primary Gastric Cancer: An Exceptional Association.

Case Rep Gastroenterol 2020 May-Aug;14(2):299-305. Epub 2020 May 28.

Department of Gastroenterology, Faculty of Medicine, Ibn Al Jazzar, University Hospital of Sahloul, Sousse, Tunisia.

Hepatocellular carcinoma (HCC) is the most frequent type of liver cancer. Liver cirrhosis of any etiology is considered the main risk factor for the development of HCC. However, HCC in noncirrhotic livers remains an uncommon finding. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000506188DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315167PMC

LncRNA FTX represses the progression of non-alcoholic fatty liver disease to hepatocellular carcinoma via regulating the M1/M2 polarization of Kupffer cells.

Cancer Cell Int 2020 24;20:266. Epub 2020 Jun 24.

Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Nanchang University, No. 1 Minde Road, Nanchang, Jiangxi Province China.

Background: The effect of lncRNA FTX on non-alcoholic fatty liver disease (NAFLD) conversion to hepatocellular carcinoma (HCC) is unclear.

Methods: In our study, C57BL/6 mice was fed with high fat diet for obtaining NAFLD mouse model, and diethylnitrosamine induced the formation of HCC tumor. The expression of iNOS and CD206 in tissues were examined using immunohistochemistry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12935-020-01354-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315496PMC

Simultaneous primary hepatocellular carcinoma and neuroendocrine carcinoma.

Dig Liver Dis 2020 Jun 24. Epub 2020 Jun 24.

Division of Gastroenterology, Department of Internal Medicine, Sapporo Shirakaba-dai Hospital, 2-18 Tsukisamu-Higashi, Toyohira-ku, Sapporo 062-0052, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.dld.2020.05.049DOI Listing

Primary hepatic neuroendocrine carcinoma coexisting with distal cholangiocarcinoma: A case report and review of the literature.

Medicine (Baltimore) 2020 Jun;99(26):e20854

Department of Pathology, Third Central Hospital of Tianjin, Tianjin Third Central Hospital affiliated to Nankai University, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases.

Introduction: Although primary hepatic neuroendocrine carcinomas, whose prognostic mechanisms remain unclear, are rare, coexistence of neuroendocrine carcinomas and other tumors is rarer. In this report, we describe a unique case of coexistence between primary hepatic neuroendocrine carcinoma and a distal cholangiocarcinoma in the pancreas.

Patient Concerns: A 64-year-old woman with a history of diabetes, but none of hepatitis, was admitted to hospital because of intermittent epigastric distension and pain discomfort for more than 1 month aggravated 1 day. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000020854DOI Listing

Clinical Impact of Antecedent Bariatric Surgery on Liver Transplant Outcomes: A Retrospective Matched Case-control Study.

Transplantation 2020 Jun 23. Epub 2020 Jun 23.

Division of Transplantation, Department of Surgery, University of Minnesota Medical School, Minneapolis, Minnesota, U.S.A.

Background: Bariatric surgery (BS) may be associated with significant malabsorption and nutritional deficiencies.

Methods: Between March 1987 and January 2017, we performed 922 liver transplants (LT) at our institution; 33 had antecedent BS. We matched the BS cohort to LT recipients without BS (1:3 matching) based on exact matching for gender and cancer and inverse variance matching for age, LT BMI, MELD score, and transplant date. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/TP.0000000000003378DOI Listing

Educating Primary Care Providers and Associate Care Providers About Hepatitis C Screening of Baby Boomers: a Multi-practice Study.

J Cancer Educ 2020 Jun 25. Epub 2020 Jun 25.

Gehr Center for Health Systems Science and Innovation, Keck School of Medicine, University of Southern California, 2020 Zonal Dr IRD 322, Los Angeles, CA, 91202, USA.

Chronic hepatitis C virus (HCV) increases the risk for hepatocellular carcinoma. Despite higher prevalence of HCV in persons born 1945-1965 (baby boomer), screening has not been widely adopted. Both primary care providers (PCPs) and associate care providers (ACPs) need to be educated about the rationale and methods to screen for HCV. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13187-020-01805-2DOI Listing

Distal Pancreatectomy with Celiac Axis Resection (Modified Appleby Procedure) and Arterial Reconstruction for Locally Advanced Pancreatic Adenocarcinoma After FOLFIRINOX Chemotherapy and Chemoradiation Therapy.

Ann Surg Oncol 2020 Jun 25. Epub 2020 Jun 25.

Department of Surgical Oncology, Institut du Cancer de Montpellier (ICM), Montpellier, France.

Background: Resectability of pancreatic carcinoma (PC) is directly linked to vascular extension (Tempero MA et al. in J Natl Compr Canc Netw 15(8):1028-1061, 2017. https://doi. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-020-08740-yDOI Listing

Gadoxetate-enhanced abbreviated MRI is highly accurate for hepatocellular carcinoma screening.

Eur Radiol 2020 Jun 25. Epub 2020 Jun 25.

BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Objectives: The primary objective was to compare the performance of 3 different abbreviated MRI (AMRI) sets extracted from a complete gadoxetate-enhanced MRI obtained for hepatocellular carcinoma (HCC) screening. Secondary objective was to perform a preliminary cost-effectiveness analysis, comparing each AMRI set to published ultrasound performance for HCC screening in the USA.

Methods: This retrospective study included 237 consecutive patients (M/F, 146/91; mean age, 58 years) with chronic liver disease who underwent a complete gadoxetate-enhanced MRI for HCC screening in 2017 in a single institution. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00330-020-07014-1DOI Listing

[CUP in the liver].

Pathologe 2020 Jun 25. Epub 2020 Jun 25.

Institut für Pathologie,an den Universitätskliniken Bergmannsheil, Ruhr-Universität Bochum, Bürkle de la Camp-Platz 1, 44789, Bochum, Deutschland.

Hepatic involvement is one of the most common manifestations in cancer of unknown primary (CUP) syndrome. The most frequent secondary neoplasms of the liver are carcinomas and malignant melanomas. Most common carcinoma metastases are adenocarcinomas originating from the digestive system or metastases of breast and lung carcinomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00292-020-00803-xDOI Listing

Hepatic neuroendocrine neoplasm: imaging patterns.

Radiol Bras 2020 May-Jun;53(3):195-200

Escola Paulista de Medicina da Universidade Federal de São Paulo (EPM-Unifesp), São Paulo, SP, Brazil.

Neuroendocrine neoplasms (NENs) are a heterogeneous group of tumors with distinct morphological and biological manifestations, the liver being the main organ affected by its metastases. However, primary hepatic involvement is quite rare. Hepatic NENs can have a variety of radiological presentation forms and can therefore mimic other lesions, making their diagnosis challenging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/0100-3984.2019.0038DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302895PMC

Molecular Bases of Drug Resistance in Hepatocellular Carcinoma.

Cancers (Basel) 2020 Jun 23;12(6). Epub 2020 Jun 23.

Experimental Hepatology and Drug Targeting (HEVEFARM) Group, University of Salamanca, IBSAL, 37007 Salamanca, Spain.

The poor outcome of patients with non-surgically removable advanced hepatocellular carcinoma (HCC), the most frequent type of primary liver cancer, is mainly due to the high refractoriness of this aggressive tumor to classical chemotherapy. Novel pharmacological approaches based on the use of inhibitors of tyrosine kinases (TKIs), mainly sorafenib and regorafenib, have provided only a modest prolongation of the overall survival in these HCC patients. The present review is an update of the available information regarding our understanding of the molecular bases of mechanisms of chemoresistance (MOC) with a significant impact on the response of HCC to existing pharmacological tools, which include classical chemotherapeutic agents, TKIs and novel immune-sensitizing strategies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12061663DOI Listing

Primary hepatic mucosa-associated lymphoid tissue lymphoma with hepatocellular carcinoma: a case report and literature review.

J Dig Dis 2020 Jun 25. Epub 2020 Jun 25.

Department of Hematology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1751-2980.12917DOI Listing

Renal metastasis from primary hepatocellular carcinoma: a case report.

Int Cancer Conf J 2020 Jul 25;9(3):141-145. Epub 2020 Mar 25.

Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551 Japan.

We report a rare case of renal metastasis from primary hepatocellular carcinoma (HCC). A mass in the right kidney of a 71-year-old man was detected by follow-up computed tomography (CT) for HCC. He was diagnosed as having primary HCC 18 years ago and had undergone partial hepatectomy, transarterial chemoembolization, and pulmonary segmentectomy for primary HCC and its metastasis over 10 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13691-020-00409-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297933PMC

Hepatic venous pressure gradient-guided laparoscopic splenectomy and pericardial devascularisation versus endoscopic therapy for secondary prophylaxis for variceal rebleeding in portal hypertension (CHESS1803): study protocol of a multicenter randomised controlled trial in China.

BMJ Open 2020 Jun 23;10(6):e030960. Epub 2020 Jun 23.

CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, China

Introduction: Gastro-oesophageal variceal bleeding is one of the most common and severe complications with high mortality in cirrhotic patients who developed portal hypertension. Hepatic venous pressure gradient (HVPG) is a globally recommended golden standard for the portal pressure assessment and an HVPG ≥16 mm Hg indicates a higher risk of death and rebleeding. This study aims to compare the effectiveness and safety of splenectomy and pericardial devascularisation (laparoscopic therapy) plus propranolol and endoscopic therapy plus propranolol for variceal rebleeding in cirrhotic patients with HVPG between 16 and 20 mm Hg. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmjopen-2019-030960DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312451PMC

Serum REIC/Dickkopf-3 Protein Level Predicts Disease-Free Survival in Patients with Hepatocellular Carcinoma.

Acta Med Okayama 2020 Jun;74(3):237-243

Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.

The physiological role of the reduced expression of immortalized cells (REIC)/Dickkopf-3 (Dkk-3) protein in patients with hepatocellular carcinoma (HCC) remains unclear. In this study, we evaluated the effect of the REIC/Dkk-3 protein on HCC cell proliferation and assessed the relationship between the serum REIC/Dkk-3 protein level and the prognosis in patients with HCC. We evaluated the REIC/Dkk-3 protein-induced anticancer effects on Huh7 and Hep3B cells (HCC cell lines) in the presence of peripheral blood mononuclear cells (PBMCs), and found that combination treatment with REIC/Dkk-3 protein and PBMCs reduced the proliferation of HCC cells (Hep3B: 82. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18926/AMO/59957DOI Listing

Relationship between presarcopenia and event occurrence in patients with primary hepatocellular carcinoma.

Sci Rep 2020 Jun 23;10(1):10186. Epub 2020 Jun 23.

First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.

Presarcopenia is a prognostic factor in patients with hepatocellular carcinoma (HCC). The Japan integrated staging (JIS) score is a prognostic method that combines the Child-Turcotte-Pugh classification and the tumor-node-metastasis (TNM) staging for HCC. We investigated the relationship between presarcopenia, the JIS score, and prognosis in patients with primary HCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-67147-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311529PMC

Efficacy and safety of radiotherapy for primary liver cancer.

Chin Clin Oncol 2020 Jun 11. Epub 2020 Jun 11.

Radiation Medicine Program, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.

Primary liver cancer includes hepatocellular carcinoma (HCC, 75-85%) and intrahepatic cholangiocarcinoma (10-15%). The vast majority of patients with primary HCC are not candidates for surgical treatment. Surgical resection, liver transplantation and percutaneous puncture are effective potentially curable treatments for patients with early stage liver cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco-20-89DOI Listing

Long-term outcomes of patients undergoing liver transplantation for acute-on-chronic liver failure.

Liver Transpl 2020 Jun 23. Epub 2020 Jun 23.

Leonard David Institute of Health Economics, University of Pennsylvania, Philadelphia, PA, USA.

Aims: Recent data have demonstrated greater than 80% one-year survival probability after liver transplantation (LT) for patients with severe acute on chronic liver failure (ACLF). However, long term outcomes and complications are still unknown for this population. Our aim was to compare long-term patient and graft survival among patients transplanted across all grades of ACLF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/lt.25831DOI Listing